Logos Global Management
Latest statistics and disclosures from Logos Global Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, XBI, SRPT, SRPT, APLS, and represent 27.00% of Logos Global Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$185M), APLS (+$61M), ARGX (+$58M), MRUS (+$50M), RVMD (+$47M), IRON (+$42M), MLTX (+$33M), JANX (+$25M), XNCR (+$16M), GPCR (+$15M).
- Started 17 new stock positions in SKYE, BHVN, IONS, MLTX, XENE, RAPP, NUVL, XBI, ARGX, RLAY. AVTX, RNAC, RVMD, IRON, ERAS, MRUS, STOK.
- Reduced shares in these 10 stocks: SRPT (-$150M), , IMCR (-$59M), DYN (-$52M), IMVT (-$32M), GERN (-$30M), CLDX (-$27M), ELVN (-$23M), RCKT (-$21M), ATXS (-$16M).
- Sold out of its positions in ALNY, CLDX, CGON, CGEM, CYTK, GERN, IMCR, IMUX, KURA, KYTX. LRMR, LPTX, PRAX, SNDX, TRML, VRDN, IMTX.
- Logos Global Management was a net buyer of stock by $87M.
- Logos Global Management has $2.5B in assets under management (AUM), dropping by 100.32%.
- Central Index Key (CIK): 0001792126
Tip: Access up to 7 years of quarterly data
Positions held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Logos Global Management
Logos Global Management holds 103 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 7.5 | $185M | NEW | 2.0M | 92.71 |
|
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 7.5 | $185M | NEW | 2.0M | 92.71 |
|
| Sarepta Therapeutics (SRPT) | 4.1 | $103M | -59% | 650k | 158.00 |
|
| Sarepta Therapeutics Call Option (SRPT) | 4.1 | $103M | -59% | 650k | 158.00 |
|
| Apellis Pharmaceuticals Call Option (APLS) | 3.7 | $92M | +200% | 2.4M | 38.36 |
|
| Apellis Pharmaceuticals (APLS) | 3.7 | $92M | +200% | 2.4M | 38.36 |
|
| Structure Therapeutics Sponsored Ads Call Option (GPCR) | 2.5 | $61M | +32% | 1.6M | 39.27 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.5 | $61M | +32% | 1.6M | 39.27 |
|
| Ideaya Biosciences (IDYA) | 2.4 | $60M | +13% | 1.7M | 35.11 |
|
| Ideaya Biosciences (IDYA) | 2.4 | $60M | +13% | 1.7M | 35.11 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.3 | $58M | NEW | 135k | 430.04 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.3 | $58M | NEW | 135k | 430.04 |
|
| Merus N V (MRUS) | 2.0 | $50M | NEW | 850k | 59.17 |
|
| Merus N V (MRUS) | 2.0 | $50M | NEW | 850k | 59.17 |
|
| Revolution Medicines (RVMD) | 1.9 | $47M | NEW | 1.2M | 38.81 |
|
| Revolution Medicines (RVMD) | 1.9 | $47M | NEW | 1.2M | 38.81 |
|
| Disc Medicine (IRON) | 1.7 | $42M | NEW | 925k | 45.07 |
|
| Disc Medicine (IRON) | 1.7 | $42M | NEW | 925k | 45.07 |
|
| Ocular Therapeutix (OCUL) | 1.4 | $35M | -11% | 5.2M | 6.84 |
|
| Ocular Therapeutix (OCUL) | 1.4 | $35M | -11% | 5.2M | 6.84 |
|
| Olema Pharmaceuticals (OLMA) | 1.4 | $35M | -26% | 3.2M | 10.82 |
|
| Olema Pharmaceuticals (OLMA) | 1.4 | $35M | -26% | 3.2M | 10.82 |
|
| Vera Therapeutics Cl A (VERA) | 1.4 | $34M | +65% | 950k | 36.18 |
|
| Vera Therapeutics Cl A (VERA) | 1.4 | $34M | +65% | 950k | 36.18 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.3 | $33M | NEW | 750k | 43.97 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 1.3 | $33M | NEW | 750k | 43.97 |
|
| Janux Therapeutics (JANX) | 1.3 | $31M | +400% | 750k | 41.89 |
|
| Janux Therapeutics (JANX) | 1.3 | $31M | +400% | 750k | 41.89 |
|
| Xencor (XNCR) | 1.1 | $28M | +130% | 1.5M | 18.93 |
|
| Xencor (XNCR) | 1.1 | $28M | +130% | 1.5M | 18.93 |
|
| Silence Therapeutics Ads (SLN) | 1.1 | $28M | 1.5M | 19.00 |
|
|
| Silence Therapeutics Ads (SLN) | 1.1 | $28M | 1.5M | 19.00 |
|
|
| Annexon (ANNX) | 1.0 | $24M | +18% | 4.8M | 4.90 |
|
| Annexon (ANNX) | 1.0 | $24M | +18% | 4.8M | 4.90 |
|
| Akero Therapeutics (AKRO) | 0.8 | $19M | 800k | 23.46 |
|
|
| Akero Therapeutics (AKRO) | 0.8 | $19M | 800k | 23.46 |
|
|
| Design Therapeutics (DSGN) | 0.7 | $17M | 5.0M | 3.35 |
|
|
| Design Therapeutics (DSGN) | 0.7 | $17M | 5.0M | 3.35 |
|
|
| Immunovant (IMVT) | 0.6 | $15M | -67% | 575k | 26.40 |
|
| Immunovant (IMVT) | 0.6 | $15M | -67% | 575k | 26.40 |
|
| Nuvalent Inc-a (NUVL) | 0.6 | $15M | NEW | 195k | 75.86 |
|
| Nuvalent Inc-a (NUVL) | 0.6 | $15M | NEW | 195k | 75.86 |
|
| Xenon Pharmaceuticals (XENE) | 0.6 | $15M | NEW | 375k | 38.99 |
|
| Xenon Pharmaceuticals (XENE) | 0.6 | $15M | NEW | 375k | 38.99 |
|
| Ionis Pharmaceuticals (IONS) | 0.6 | $14M | NEW | 300k | 47.66 |
|
| Ionis Pharmaceuticals (IONS) | 0.6 | $14M | NEW | 300k | 47.66 |
|
| Stoke Therapeutics (STOK) | 0.6 | $14M | NEW | 1.1M | 13.51 |
|
| Stoke Therapeutics (STOK) | 0.6 | $14M | NEW | 1.1M | 13.51 |
|
| Erasca (ERAS) | 0.6 | $14M | NEW | 5.9M | 2.36 |
|
| Erasca (ERAS) | 0.6 | $14M | NEW | 5.9M | 2.36 |
|
| Enliven Therapeutics (ELVN) | 0.6 | $14M | -62% | 595k | 23.37 |
|
| Enliven Therapeutics (ELVN) | 0.6 | $14M | -62% | 595k | 23.37 |
|
| Spyre Therapeutics Com New (SYRE) | 0.5 | $14M | +130% | 575k | 23.51 |
|
| Spyre Therapeutics Com New (SYRE) | 0.5 | $14M | +130% | 575k | 23.51 |
|
| Engene Holdings (ENGN) | 0.5 | $11M | +50% | 1.2M | 9.43 |
|
| Engene Holdings (ENGN) | 0.5 | $11M | +50% | 1.2M | 9.43 |
|
| Cybin Ord (CYBN) | 0.4 | $11M | 40M | 0.27 |
|
|
| Cybin Ord (CYBN) | 0.4 | $11M | 40M | 0.27 |
|
|
| Skye Bioscience Com New (SKYE) | 0.4 | $10M | NEW | 1.3M | 8.01 |
|
| Skye Bioscience Com New (SKYE) | 0.4 | $10M | NEW | 1.3M | 8.01 |
|
| Elevation Oncology (ELEV) | 0.4 | $10M | +285% | 3.9M | 2.70 |
|
| Elevation Oncology (ELEV) | 0.4 | $10M | +285% | 3.9M | 2.70 |
|
| Dyne Therapeutics (DYN) | 0.4 | $9.4M | -84% | 265k | 35.29 |
|
| Dyne Therapeutics (DYN) | 0.4 | $9.4M | -84% | 265k | 35.29 |
|
| Fulcrum Therapeutics Call Option (FULC) | 0.4 | $9.3M | +50% | 1.5M | 6.20 |
|
| Fulcrum Therapeutics Call Option (FULC) | 0.4 | $9.3M | +50% | 1.5M | 6.20 |
|
| Biohaven (BHVN) | 0.4 | $8.7M | NEW | 250k | 34.71 |
|
| Biohaven (BHVN) | 0.4 | $8.7M | NEW | 250k | 34.71 |
|
| Relay Therapeutics (RLAY) | 0.3 | $8.5M | NEW | 1.3M | 6.52 |
|
| Relay Therapeutics (RLAY) | 0.3 | $8.5M | NEW | 1.3M | 6.52 |
|
| Trevi Therapeutics (TRVI) | 0.3 | $8.3M | +27% | 2.8M | 2.98 |
|
| Trevi Therapeutics (TRVI) | 0.3 | $8.3M | +27% | 2.8M | 2.98 |
|
| Rocket Pharmaceuticals (RCKT) | 0.3 | $7.5M | -73% | 350k | 21.53 |
|
| Rocket Pharmaceuticals (RCKT) | 0.3 | $7.5M | -73% | 350k | 21.53 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $7.0M | +349% | 1.2M | 6.04 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $7.0M | +349% | 1.2M | 6.04 |
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $6.7M | NEW | 539k | 12.47 |
|
| Lineage Cell Therapeutics In (LCTX) | 0.2 | $4.7M | -24% | 4.7M | 1.00 |
|
| Lineage Cell Therapeutics In (LCTX) | 0.2 | $4.7M | -24% | 4.7M | 1.00 |
|
| Atyr Pharma Com New (ATYR) | 0.2 | $4.7M | -3% | 3.0M | 1.56 |
|
| Atyr Pharma Com New (ATYR) | 0.2 | $4.7M | -3% | 3.0M | 1.56 |
|
| Astria Therapeutics (ATXS) | 0.2 | $4.6M | -77% | 500k | 9.10 |
|
| Astria Therapeutics (ATXS) | 0.2 | $4.6M | -77% | 500k | 9.10 |
|
| Rapport Therapeutics (RAPP) | 0.2 | $4.4M | NEW | 209k | 20.93 |
|
| Nextcure (NXTC) | 0.2 | $4.0M | +29% | 2.5M | 1.59 |
|
| Nextcure (NXTC) | 0.2 | $4.0M | +29% | 2.5M | 1.59 |
|
| Neumora Therapeutics (NMRA) | 0.1 | $2.9M | -21% | 300k | 9.83 |
|
| Neumora Therapeutics (NMRA) | 0.1 | $2.9M | -21% | 300k | 9.83 |
|
| Allakos (ALLK) | 0.1 | $2.9M | 2.9M | 1.00 |
|
|
| Allakos (ALLK) | 0.1 | $2.9M | 2.9M | 1.00 |
|
|
| Adverum Biotechnologies Com New (ADVM) | 0.1 | $2.9M | -72% | 417k | 6.86 |
|
| Adverum Biotechnologies Com New (ADVM) | 0.1 | $2.9M | -72% | 417k | 6.86 |
|
| Applied Therapeutics (APLT) | 0.1 | $2.7M | -55% | 600k | 4.44 |
|
| Applied Therapeutics (APLT) | 0.1 | $2.7M | -55% | 600k | 4.44 |
|
| Cartesian Therapeutics Com New (RNAC) | 0.1 | $2.4M | NEW | 90k | 27.01 |
|
| Cartesian Therapeutics Com New (RNAC) | 0.1 | $2.4M | NEW | 90k | 27.01 |
|
| Unicycive Therapeutics (UNCY) | 0.1 | $1.7M | 3.5M | 0.50 |
|
|
| Unicycive Therapeutics (UNCY) | 0.1 | $1.7M | 3.5M | 0.50 |
|
|
| Io Biotech (IOBT) | 0.0 | $578k | 494k | 1.17 |
|
|
| Io Biotech (IOBT) | 0.0 | $578k | 494k | 1.17 |
|
|
| Boundless Bio (BOLD) | 0.0 | $433k | -41% | 118k | 3.68 |
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $11k | 67k | 0.16 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $11k | 67k | 0.16 |
|
Past Filings by Logos Global Management
SEC 13F filings are viewable for Logos Global Management going back to 2019
- Logos Global Management 2024 Q2 amended filed Aug. 27, 2024
- Logos Global Management 2024 Q2 filed Aug. 14, 2024
- Logos Global Management 2024 Q1 filed May 15, 2024
- Logos Global Management 2023 Q4 filed Feb. 14, 2024
- Logos Global Management 2023 Q3 filed Nov. 14, 2023
- Logos Global Management 2023 Q2 filed Aug. 14, 2023
- Logos Global Management 2023 Q1 filed May 15, 2023
- Logos Global Management 2022 Q4 filed Feb. 14, 2023
- Logos Global Management 2022 Q3 filed Nov. 14, 2022
- Logos Global Management 2022 Q2 filed Aug. 15, 2022
- Logos Global Management 2022 Q1 filed May 16, 2022
- Logos Global Management 2021 Q4 filed Feb. 14, 2022
- Logos Global Management 2021 Q3 filed Nov. 15, 2021
- Logos Global Management 2021 Q2 restated filed Aug. 17, 2021
- Logos Global Management 2021 Q2 filed Aug. 16, 2021
- Logos Global Management 2021 Q1 filed May 17, 2021